Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia

Psychiatria Danubina

Volumn 11, Issue 1-2, 1999, Pages 3-11

  Jakovljević, Miro ^a   Dossenbach, Martin R ^b   Friedel, Philipp ^b   Schausberger, Barbara ^b   Grundy, Starr Lee ^c   Hotujac, Ljubomir ^a   Folnegović Šmalc, Vera ^d   Uglešić, Borben ^e   Tollefson, Gary D ^c  

^a KBC Zagreb   (Croatia)

^b Lilly Area Medical Center   (Austria)

^c ELI LILLY AND COMPANY   (United States)

^d Psychiatric Hospital Vrap e   (Croatia)

^e Psychiatric Clinic Split   (Croatia)

Author keywords

Fluphenazine; Olanzapine; Psychosis; Schizophrenia

Indexed keywords

EID: 0002339379     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Andreasen, N.C.: Symptoms, signs and diagnosis of schizo phrenia. Lancet, 1995; 346, 477-481.
2. Beasley, CM., Jr., Sanger, T., Satterlee, W., Tollefson, G., Tran, P & Hamilton, S.: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 1996a; 124,159-167.
3. Beasley, CM., Jr., Tollefson, G., Tran, P.V., Satterlee, W., Sanger, T, Hamilton, S. & Olanzapine HGAD Study Group: Olanzapine versus placebo and haloperidol. Acute phase re suits of the North American double-blind olanzapine trial. Neuropsychopharmacology,1996b;14, 111-123.
4. Carlsson, A.: Neurocircuitries and neurotransmitter interaction in schizophrenia. International Clinical Psychopharmacology, 1995; 10,21-28.
5. Dossenbach, M., Friedel, P., Folnegović, V., Jakovljević, M., Hotujac, Lj, Uglešić, B. & Dodig, G.: Olanzapine versus fluphenazine - 6 weeks treatment of schizophrenia.European Neuropsychopharmacology, 1997;7 (Suppl 2), S222.
6. Fleischhacker, W.W., Bergmann, K.J., Perovich, R., Pestreich, L.K., Borenstein, M., Lieberman, J.A. & Kane, J.M.: The Hillside Akathisia Scale: a new rating instrument for neuro lepticinduced akathisia. Psychopharmacology Bulletin, 1989; 25, 222-226.
7. Guy, W.: (1976) ECDEU Assessment Manual far Psychopharmacolog, US Department of Health, Education and Welfare. Rockville, MD.
8. Hamilton, M.: The assessment of anxiety states by rating. British Journal of Medical Psychology, 1959; 32, 50-55.
9. Jakovljević, M., Dossenbach, M., Tollefson, G.D., Hotujac, Lj, Folnegović-Šmalc, V., Dodig, G. Uglesic, B. & Miličević, Z.; Antipsychotic and anxiolytic properties of olanzapine versus fluphenazine in schizophrenic patients: results of Croatian study. Psychiatria Danubina, 1998; 10, 181-184.
10. Kay, S., Opler; L. & Fiszbein, A.: (1986) Positive and Negative Syndrome Scale (PANSS) Manual, Multi-Health Systems, North Tonawanda.
11. Lehman A.F.: Evaluating outcomes of treatments for persons with psychotic disorders. Journal of Clinical Psychiatry, 1996; 57 (Suppl 11), 61-67.
12. Meltzer, H.Y.: Treatment of the neuroleptic-nonresponsive schizophrenic patient. [Review] [221 refs]. Schizophrenia Bulletin, 1992; 18, 515-542.
13. Parrott, A.C. & Hindmarch, I.: The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopliannacology. 1980; 71, 173-179.
14. Simpson, G.M. & Angus, J.W.S.: A rating scale for extrapy ramidal side effects. Acta Psychiatrica Scandinavica, 1970; 212, S11-S19
15. Tollefson, G.D., Beasley, CM., Jr., Tran, P.V., Street, J.S., Krueger, JA, Tamura, R.N., Graffeo, K.A. & Thieme, M.E.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 1997; 154,457-465.
16. Tollefson, G.D. & Sanger, T.M.: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperi dol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 1997; 154,466-474.
17. Tran, P.V, Dellva, M.A., Tollefson, G.D., Beasley, CM., Jr., Potvin, J.H. & Kiesler, G.M.: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry, 1997a; 58, 205-211.
18. Tran, P.V., Hamilton, S.H., Kuntz, A.J., Potvin, J.H., Andersen, S.W., Beasley, C.M.Jr. & Tollefson, G.D.; Doubleblind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disor ders. Journal of Clinical Psychopharmacology, 1997b; 17, 407-418.
19. Weiden, P.J., Shaw, E. & Mann, J.J.; Causes of neuroleptic noncompliance. Psychiatric Annals, 1986; 16, 571-575.